JP2011521964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521964A5 JP2011521964A5 JP2011511822A JP2011511822A JP2011521964A5 JP 2011521964 A5 JP2011521964 A5 JP 2011521964A5 JP 2011511822 A JP2011511822 A JP 2011511822A JP 2011511822 A JP2011511822 A JP 2011511822A JP 2011521964 A5 JP2011521964 A5 JP 2011521964A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- group
- use according
- alkyl
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 201000006938 muscular dystrophy Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 208000020431 spinal cord injury Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 150000003573 thiols Chemical class 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 2
- 150000001408 amides Chemical group 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical group CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 241001317099 Dystaxia Species 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims 1
- 206010070531 Foetal growth restriction Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 1
- 206010024238 Leptospirosis Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000003435 aroyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000001925 catabolic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002169 ectodermal dysplasia Diseases 0.000 claims 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 claims 1
- 208000030941 fetal growth restriction Diseases 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000010346 psychosocial stress Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 150000003456 sulfonamides Chemical group 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5671508P | 2008-05-28 | 2008-05-28 | |
| US61/056,715 | 2008-05-28 | ||
| PCT/US2009/045489 WO2009155056A2 (en) | 2008-05-28 | 2009-05-28 | Non-hormonal steroid modulators of nf-kb for treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015116880A Division JP6204408B2 (ja) | 2008-05-28 | 2015-06-09 | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521964A JP2011521964A (ja) | 2011-07-28 |
| JP2011521964A5 true JP2011521964A5 (https=) | 2012-07-12 |
| JP5780521B2 JP5780521B2 (ja) | 2015-09-16 |
Family
ID=41434650
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511822A Active JP5780521B2 (ja) | 2008-05-28 | 2009-05-28 | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
| JP2015116880A Active JP6204408B2 (ja) | 2008-05-28 | 2015-06-09 | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
| JP2017167132A Active JP6356888B2 (ja) | 2008-05-28 | 2017-08-31 | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015116880A Active JP6204408B2 (ja) | 2008-05-28 | 2015-06-09 | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
| JP2017167132A Active JP6356888B2 (ja) | 2008-05-28 | 2017-08-31 | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US8207151B2 (https=) |
| EP (5) | EP3656385A1 (https=) |
| JP (3) | JP5780521B2 (https=) |
| KR (3) | KR101749032B1 (https=) |
| CN (3) | CN102076344B (https=) |
| AU (1) | AU2009260471B2 (https=) |
| BR (1) | BRPI0909564B8 (https=) |
| CA (1) | CA2725008C (https=) |
| CY (2) | CY1121984T1 (https=) |
| DK (3) | DK2444092T3 (https=) |
| ES (3) | ES2548138T3 (https=) |
| FI (1) | FIC20240018I1 (https=) |
| FR (1) | FR24C1021I2 (https=) |
| HK (1) | HK1201184A1 (https=) |
| HR (1) | HRP20191455T1 (https=) |
| HU (4) | HUE027463T2 (https=) |
| LT (2) | LT2805720T (https=) |
| MX (1) | MX2010012976A (https=) |
| NL (1) | NL301273I2 (https=) |
| NZ (2) | NZ589444A (https=) |
| PL (1) | PL2805720T3 (https=) |
| PT (1) | PT2805720T (https=) |
| SI (1) | SI2805720T1 (https=) |
| WO (1) | WO2009155056A2 (https=) |
| ZA (1) | ZA201008256B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5780521B2 (ja) | 2008-05-28 | 2015-09-16 | リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎ ＢｉｏＰｈａｒｍａ，Ｉｎｃ． | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
| WO2011127048A2 (en) * | 2010-04-05 | 2011-10-13 | Validus Biopharma | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE |
| US10464967B2 (en) * | 2011-11-29 | 2019-11-05 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
| CN103509075A (zh) * | 2012-06-29 | 2014-01-15 | 中国药科大学 | 一种制备二氟泼尼酯的方法 |
| WO2017004205A1 (en) | 2015-06-29 | 2017-01-05 | Reveragen Biopharma, Inc. | NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE |
| MX382122B (es) * | 2015-07-06 | 2025-03-13 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| IL264561A (en) * | 2019-01-31 | 2020-08-31 | Lydus Medical Ltd | device for anastomosis |
| US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| WO2023049689A1 (en) * | 2021-09-21 | 2023-03-30 | Reveragen Biopharma, Inc. | Treatment of congenital adrenal hypoplasia |
| EP4413976B1 (en) * | 2023-02-07 | 2025-08-13 | Santhera Pharmaceuticals (Schweiz) AG | A new vamorolone preparation exhibiting improved solubility |
Family Cites Families (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US619456A (en) * | 1899-02-14 | Adjustable partition-frame for trunks | ||
| GB787410A (en) | 1954-05-21 | 1957-12-11 | Pfizer & Co C | Improvements in or relating to steroid compounds and the preparation thereof |
| GB843215A (en) | 1954-10-05 | 1960-08-04 | Schering Corp | Improvements in or relating to steroid compounds |
| GB843214A (en) | 1955-01-11 | 1960-08-04 | Schering Corp | Improvements in or relating to steroid compounds |
| US2957893A (en) * | 1955-01-20 | 1960-10-25 | Schering Corp | delta1, 4, 9(11)-pregnatrienes |
| US2776927A (en) * | 1955-12-27 | 1957-01-08 | Pfizer & Co C | Preparation of delta 1, 4-3-keto steroids from delta4 3-keto steroids by protaminobacter |
| US3164618A (en) | 1957-07-22 | 1965-01-05 | Schering Corp | Alkylated steroids |
| US2838536A (en) * | 1957-11-29 | 1958-06-10 | Upjohn Co | 6-fluoro 9 alpha-halo-delta4-pregnenes and process for preparing same |
| GB912379A (en) | 1958-06-19 | 1962-12-05 | Merck & Co Inc | Steroid compounds |
| GB928301A (en) | 1958-06-20 | 1963-06-12 | Scherico Ltd | 9, 11-dihalogeno steroids |
| US2894963A (en) * | 1958-06-20 | 1959-07-14 | Scherico Ltd | 9,11-dihalogeno-4-pregnenes and 1,4-pregnadienes |
| US2980713A (en) * | 1958-09-05 | 1961-04-18 | Merck & Co Inc | 16-methyl-3alpha, 17alpha-dihydroxy steroids of the pregnane series |
| US3098086A (en) * | 1959-01-22 | 1963-07-16 | Ciba Geigy Corp | Process for the manufacture of 11beta-hydroxy-pregnane compounds |
| US3009933A (en) * | 1959-06-01 | 1961-11-21 | Schering Corp | Process for the manufacture of 9alpha, 11beta-dihalogenated steroids |
| FR1433301A (fr) | 1959-06-12 | 1966-04-01 | Merck & Co Inc | Procédé de préparation de composés de 16alpha-méthyl, 1, 4-prégnadiène |
| US3004965A (en) * | 1959-08-07 | 1961-10-17 | Smith Kline French Lab | Process and intermediates for preparing steroidal 17->18 lactones |
| GB959377A (en) | 1959-10-12 | 1964-06-03 | Scherico Ltd | Dioxy steroids and processes for their preparation |
| FR1363865A (fr) | 1960-06-16 | 1964-06-19 | Roussel Uclaf | Nouveaux stéroïdes polyhydroxylés et obtention de ces composés |
| US3053866A (en) * | 1961-03-02 | 1962-09-11 | Merck & Co Inc | Improved steroid dehydrogenation process |
| US3127425A (en) * | 1961-05-29 | 1964-03-31 | Schering Corp | 6, 17alpha-disubstituted 9alpha, 11beta-dihalogeno derivatives of a-ring unsaturated pregnane 3, 20-diones |
| US3047468A (en) * | 1961-06-06 | 1962-07-31 | American Cyanamid Co | Method of preparing delta1, 4-3-keto steroids of the pregnane series |
| US3087938A (en) * | 1961-08-02 | 1963-04-30 | Schering Corp | 17alpha-chloro and 17alpha-bromo-progesterones |
| US3284477A (en) | 1963-07-10 | 1966-11-08 | Schering Corp | Diuretic 1, 4, 9(11)-pregnatrienes |
| US3463852A (en) * | 1966-01-14 | 1969-08-26 | Schering Corp | Treating allergies with steroids of the pregnane series |
| DE1938218C3 (de) * | 1969-07-24 | 1978-10-19 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 9 a,21,21-Trichlor-ll ß-fluor- pregnene, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel |
| HU164115B (https=) | 1971-05-07 | 1973-12-28 | ||
| BE785812A (fr) | 1971-07-05 | 1973-01-04 | Glaxo Lab Ltd | Nouveaux composes steroides |
| BE795243A (fr) * | 1972-02-11 | 1973-08-09 | Schering Ag | Procede de preparation de steroides insatures en 16,17 |
| GB1440063A (en) * | 1972-08-11 | 1976-06-23 | Glaxo Lab Ltd | 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids |
| FR2244530B1 (https=) * | 1973-07-27 | 1977-07-01 | Roussel Uclaf | |
| US4041055A (en) * | 1975-11-17 | 1977-08-09 | The Upjohn Company | Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes |
| ES445981A1 (es) | 1976-03-11 | 1977-06-01 | Aldo Union Calzada Y Cia S R C | Procedimiento para la preparacion de un compuesto intermedioen la sintesis de 9 alfa-halogeno-16 beta-metil-prednisolo- na. |
| GB1544642A (en) | 1976-06-04 | 1979-04-25 | Bristol Myers Co | 9,11-epoxy steroids and synthesis of corticosteroids therefrom |
| US4076708A (en) * | 1976-12-22 | 1978-02-28 | Schering Corporation | Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby |
| DE2748442C3 (de) * | 1977-10-26 | 1981-08-27 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel |
| US4444689A (en) * | 1980-01-31 | 1984-04-24 | The Upjohn Company | 17α-Acyloxy-5β-corticoids and 17α-acyloxy-5α-corticoids |
| US4427591A (en) * | 1980-01-31 | 1984-01-24 | The Upjohn Company | Reduced A ring-Δ9(11) -corticoids |
| US4336200A (en) * | 1980-01-31 | 1982-06-22 | The Upjohn Company | 17α-Acyloxy-5β-corticoids |
| US4318853A (en) * | 1980-01-31 | 1982-03-09 | The Upjohn Company | 9β,11β-Epoxy-5β-corticoids |
| ZA817929B (en) | 1980-12-22 | 1982-10-27 | Upjohn Co | 5alpha-and 5beta-androstane-17beta-carboxylates |
| ATE8790T1 (de) * | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| DE3109459A1 (de) * | 1981-03-09 | 1982-09-23 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | (delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)(pfeil hoch)1(pfeil hoch)(pfeil hoch))(pfeil hoch)- und (delta)(pfeil hoch)1(pfeil hoch)(pfeil hoch)6(pfeil hoch)-21-chlor-20-keto-steroide der pregnan- und d-homo-pregnan-reihe, verfahren zu ihrer herstellung und ihre verwendung als zwischenprodukte fuer die synthese von hochwirksamen corticoiden |
| EP0097328B1 (en) | 1982-06-21 | 1987-08-26 | Dainippon Ink And Chemicals, Inc. | Process for preparation of steroids |
| DE3227312A1 (de) * | 1982-07-19 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6,16-dimethylkortikoide, ihre herstellung und verwendung |
| DE3322120A1 (de) | 1982-07-30 | 1984-02-02 | The Upjohn Co., 49001 Kalamazoo, Mich. | Verfahren zur umwandlung von 1,2-gesaettigten 3-ketosteroiden in 1,2-dehydrosteroide |
| DE3243482A1 (de) * | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung |
| EP0114589B1 (en) | 1982-12-20 | 1987-09-23 | The President And Fellows Of Harvard College | Inhibition of angiogenesis |
| US5001116A (en) * | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| DE3315722A1 (de) | 1983-04-27 | 1984-10-31 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur herstellung von 3-oxo-(delta)(pfeil hoch)1(pfeil hoch)(pfeil hoch),(pfeil hoch)(pfeil hoch)4(pfeil hoch)-steroiden |
| DE3401680A1 (de) * | 1984-01-16 | 1985-07-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6(alpha),16ss-dimethylkortikoide |
| DE3409554A1 (de) | 1984-03-13 | 1985-09-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6(alpha)-methyl-d-homo-kortikoide |
| US4948533A (en) * | 1984-03-28 | 1990-08-14 | The Upjohn Company | 11a-hydroxy steroid diester |
| CA1310009C (en) | 1984-03-28 | 1992-11-10 | John Mark Braughler | Ester prodrugs of steroids |
| JPS611699A (ja) * | 1984-06-11 | 1986-01-07 | ジ アツプジヨン カンパニー | １６α‐メチル化法 |
| US4990612A (en) * | 1984-06-11 | 1991-02-05 | The Upjohn Company | 16α-methylation process |
| US4613463A (en) * | 1984-11-01 | 1986-09-23 | The Upjohn Company | Process and intermediates for the preparation of 17 alphahydroxyprogesterones and corticoids from an enol steroid |
| EP0263213B1 (en) | 1986-10-09 | 1995-09-06 | The Upjohn Company | C20 Through C26 amino steroids |
| WO1987001706A2 (en) | 1985-09-12 | 1987-03-26 | The Upjohn Company | C20 through c26 amino steroids |
| US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| CN87104859A (zh) | 1986-06-19 | 1988-04-27 | Mba服务有限公司 | 带状电缆传输系统 |
| AU7580187A (en) | 1986-06-23 | 1988-01-12 | Upjohn Company, The | Androstane-type and cortical aminoesters |
| CA1317283C (en) * | 1986-11-05 | 1993-05-04 | Douglas Alan Livingston | Steroidal 17-silyl ethers and process to corticoids and progesterones |
| EP0350488B1 (en) | 1987-03-12 | 1993-09-08 | The Upjohn Company | 1,2-dehydrogenation of steroidal 21-esters with a. simplex |
| AU1704588A (en) | 1987-04-03 | 1988-11-02 | Upjohn Company, The | Amino-9,10-secosteroids |
| US4920216A (en) * | 1987-05-28 | 1990-04-24 | The Trustees Of Columbia In The City Of New York | Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates |
| US4910192A (en) * | 1987-12-04 | 1990-03-20 | Sri International | Topically active steroidal anti-inflammatory agents |
| US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
| US5990099A (en) * | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
| KR920700035A (ko) * | 1989-04-18 | 1992-02-19 | 원본 미기재 | 털 성장 억제제로서의 국소 항-맥관형성제 |
| US4975536A (en) | 1989-06-02 | 1990-12-04 | The Upjohn Company | Conversion of a delta16-steroid to a delta17(20)-20-silyl ether |
| EP0477195A1 (en) | 1989-06-16 | 1992-04-01 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| EP0489779B1 (en) * | 1989-08-28 | 1998-01-28 | Alcon Laboratories, Inc. | Ophthalmic composition |
| US5077104A (en) | 1989-12-21 | 1991-12-31 | Alza Corporation | Nicotine packaging materials |
| US6090794A (en) * | 1990-04-19 | 2000-07-18 | The General Hospital Corporation | Inhibition of neurofibrosarcoma growth and angiogenesis |
| WO1991019731A1 (en) | 1990-06-11 | 1991-12-26 | The Upjohn Company | Steroids which inhibit angiogenesis |
| US5972922A (en) * | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
| FR2675146A1 (fr) * | 1991-04-10 | 1992-10-16 | Roussel Uclaf | Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires. |
| FR2678275B1 (fr) * | 1991-06-25 | 1995-06-23 | Roussel Uclaf | Nouveaux sterouides 16-methyl substitue derives de la pregna 1,4-diene 3,20-dione leur preparation, leur application a la preparation de sterouides 16-methylene et nouveaux intermediaires. |
| HU226413B1 (en) * | 1991-06-25 | 2008-11-28 | Aventis Pharma Sa | Novel 16-(nitro-substituted methyl)pregna-1,4-dien-3,20-dion derivatives and process for producing them |
| US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| WO1993010141A2 (en) * | 1991-11-22 | 1993-05-27 | Alcon Laboratories, Inc. | Angiostatic steroids |
| CA2128860A1 (en) * | 1992-01-28 | 1993-08-05 | David R. Andrews | Novel steroid intermediates and processes for their preparation |
| HU212308B (en) | 1992-06-09 | 1996-05-28 | Richter Gedeon Vegyeszet | Process for producing novel pregnane steroids and pharmaceutical compositions containing the same |
| FR2692266B1 (fr) * | 1992-06-11 | 1994-08-05 | Roussel Uclaf | Nouveau procede de preparation de sterouides 16 alpha-methyles. |
| US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US8178516B2 (en) * | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
| FR2700548B1 (fr) * | 1993-01-20 | 1995-03-03 | Roussel Uclaf | Nouveau procédé de préparation de stéroïdes 16 alpha-méthylés. |
| US5686436A (en) | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
| US5646136A (en) | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| US5502222A (en) * | 1994-06-01 | 1996-03-26 | Schering Corporation | Process for preparing delta 9,11 and 21-chloro corticosteroids |
| CN1156962A (zh) | 1994-09-01 | 1997-08-13 | 法玛西雅厄普约翰公司 | 替瑞拉得的助溶性胃肠外给药的制剂 |
| US6011012A (en) * | 1995-06-05 | 2000-01-04 | Human Genome Sciences, Inc. | Human cystatin E |
| JP3394849B2 (ja) | 1995-06-07 | 2003-04-07 | ワイケイケイ株式会社 | 紐止め具 |
| AU1331097A (en) | 1995-12-20 | 1997-07-14 | Schering Corporation | Process for preparation of 9,11beta-epoxide steroids |
| FR2747680B1 (fr) | 1996-04-18 | 1998-07-03 | Roussel Uclaf | Nouveaux steroides, leur application a titre de medicaments, leur procede de preparation, les intermediaires de ce procede et les compositions pharmaceutiques les renfermant |
| IT1291288B1 (it) * | 1997-04-30 | 1999-01-07 | Farmabios Srl | Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22. |
| US5851812A (en) | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| US6096778A (en) | 1997-10-07 | 2000-08-01 | Cephalon, Inc. | α-ketoamide multicatalytic protease inhibitors |
| US6090798A (en) * | 1997-12-19 | 2000-07-18 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with glucocorticoid antagonists |
| US6030834A (en) | 1997-12-30 | 2000-02-29 | Chiron Corporation | Human IKK-beta DNA constructs and cells |
| ES2136581B1 (es) * | 1998-05-27 | 2000-09-16 | Uriach & Cia Sa J | Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. |
| JP2002533379A (ja) | 1998-12-23 | 2002-10-08 | イデア アクチェンゲゼルシャフト | 生体内における局所的に非侵襲性である用途のための改善された製剤 |
| RU2156256C1 (ru) | 1999-12-20 | 2000-09-20 | Андрюшина Валентина Александровна | Способ получения кортикостероидов |
| WO2002000001A2 (en) * | 2000-06-30 | 2002-01-03 | Ingenium Pharmaceuticals Ag | HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR20, AND USES THEREOF |
| AU2002236495B2 (en) * | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| JP2003081836A (ja) * | 2001-07-03 | 2003-03-19 | Univ Nihon | 低ナトリウム血症改善薬 |
| ES2184628B1 (es) * | 2001-07-26 | 2005-02-01 | Ragactives, S.L. | Procedimiento estereoselectivo para la produccion de 6alfa-fluorpregnanos intermedios. |
| ITMI20011762A1 (it) * | 2001-08-10 | 2003-02-10 | Cosmo Spa | Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| EP1535609A4 (en) | 2002-06-10 | 2009-01-07 | Inst Med Molecular Design Inc | Nf-kb activation inhibitors |
| US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| EP2298315A1 (en) | 2002-08-28 | 2011-03-23 | Harbor BioSciences, Inc. | Therapeutic treatment methods |
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| CN1968932A (zh) | 2004-06-18 | 2007-05-23 | 惠氏公司 | 制备6－烷基－5－芳基磺酰基－二氢菲啶的方法 |
| EP1618881A1 (en) * | 2004-07-20 | 2006-01-25 | Santhera Pharmaceuticals (Schweiz) GmbH | Use of non-glucocorticoid steroids for the treatment of muscular dystrophy |
| CN100551929C (zh) | 2005-07-14 | 2009-10-21 | 天津药业研究院有限公司 | Δ9(11)甾体类化合物的制备方法 |
| EP2311795A3 (en) | 2005-07-21 | 2011-12-28 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators |
| WO2007016979A2 (en) | 2005-07-29 | 2007-02-15 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
| CN1907999B (zh) | 2005-08-05 | 2010-04-28 | 天津天药药业股份有限公司 | 甲泼尼龙系列产品9,11-脱酯物生产工艺方法 |
| US20070212751A1 (en) * | 2006-01-18 | 2007-09-13 | Solvay Pharmaceuticals Gmbh | Microbial method for the 11beta hydroxylation of 9beta, 10alpha-steriods |
| US20090099191A1 (en) | 2006-02-02 | 2009-04-16 | Gudkov Andrei V | Inhibition of nf-kb |
| US8426355B2 (en) | 2006-03-15 | 2013-04-23 | Theralogics, Inc. | Methods of treating muscular wasting diseases using NF-κB activation inhibitors |
| CN101347438A (zh) | 2007-07-20 | 2009-01-21 | 天津药业研究院有限公司 | 一种减缓眼部新生血管生成的药物 |
| CN101353368A (zh) | 2007-07-27 | 2009-01-28 | 天津药业研究院有限公司 | 一种治疗肿瘤的孕甾药物 |
| CN101397319A (zh) | 2007-09-29 | 2009-04-01 | 天津天药药业股份有限公司 | 倍他米松及其系列产品的制备方法 |
| CN101397320A (zh) | 2007-09-29 | 2009-04-01 | 天津天药药业股份有限公司 | 地塞米松及其系列产品的制备方法 |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CN101434631B (zh) | 2007-11-16 | 2012-08-08 | 天津金耀集团有限公司 | 一种抑制血管新生的雌甾硝酸酯药物 |
| JP2009126852A (ja) | 2007-11-27 | 2009-06-11 | Meiji Milk Prod Co Ltd | ピリミジン誘導体を有効成分として含有する医薬組成物 |
| JP5780521B2 (ja) | 2008-05-28 | 2015-09-16 | リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎ ＢｉｏＰｈａｒｍａ，Ｉｎｃ． | 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子 |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| KR101071305B1 (ko) | 2008-10-08 | 2011-10-07 | 국립암센터 | ＡＲＨ1 단백질 또는 이를 코딩하는 유전자를 포함하는 ＮＦ―κＢ 억제제 |
| CN101759742B (zh) | 2008-11-06 | 2012-07-04 | 天津金耀集团有限公司 | 一种16α-甲基甾体化合物的制备方法 |
| WO2011127048A2 (en) * | 2010-04-05 | 2011-10-13 | Validus Biopharma | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE |
| US10464967B2 (en) | 2011-11-29 | 2019-11-05 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
| WO2017004205A1 (en) | 2015-06-29 | 2017-01-05 | Reveragen Biopharma, Inc. | NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE |
| US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
-
2009
- 2009-05-28 JP JP2011511822A patent/JP5780521B2/ja active Active
- 2009-05-28 CN CN2009801248590A patent/CN102076344B/zh active Active
- 2009-05-28 ES ES09767367.7T patent/ES2548138T3/es active Active
- 2009-05-28 BR BRPI0909564A patent/BRPI0909564B8/pt active IP Right Grant
- 2009-05-28 EP EP19190325.1A patent/EP3656385A1/en not_active Withdrawn
- 2009-05-28 HU HUE11191434A patent/HUE027463T2/en unknown
- 2009-05-28 KR KR1020177002187A patent/KR101749032B1/ko active Active
- 2009-05-28 WO PCT/US2009/045489 patent/WO2009155056A2/en not_active Ceased
- 2009-05-28 CN CN201310191579.XA patent/CN103536599A/zh active Pending
- 2009-05-28 SI SI200931992T patent/SI2805720T1/sl unknown
- 2009-05-28 EP EP22169197.5A patent/EP4049663A1/en active Pending
- 2009-05-28 NZ NZ589444A patent/NZ589444A/xx unknown
- 2009-05-28 DK DK11191434.7T patent/DK2444092T3/en active
- 2009-05-28 PT PT14173342T patent/PT2805720T/pt unknown
- 2009-05-28 US US12/473,921 patent/US8207151B2/en active Active
- 2009-05-28 DK DK14173342.8T patent/DK2805720T3/da active
- 2009-05-28 KR KR1020107029408A patent/KR101591482B1/ko active Active
- 2009-05-28 NZ NZ603107A patent/NZ603107A/en unknown
- 2009-05-28 MX MX2010012976A patent/MX2010012976A/es active IP Right Grant
- 2009-05-28 CA CA2725008A patent/CA2725008C/en active Active
- 2009-05-28 HU HUE14173342A patent/HUE046243T2/hu unknown
- 2009-05-28 ES ES14173342T patent/ES2744879T3/es active Active
- 2009-05-28 EP EP14173342.8A patent/EP2805720B1/en active Active
- 2009-05-28 EP EP09767367.7A patent/EP2278978B1/en active Active
- 2009-05-28 AU AU2009260471A patent/AU2009260471B2/en active Active
- 2009-05-28 PL PL14173342T patent/PL2805720T3/pl unknown
- 2009-05-28 LT LTEP14173342.8T patent/LT2805720T/lt unknown
- 2009-05-28 EP EP11191434.7A patent/EP2444092B1/en active Active
- 2009-05-28 CN CN201310485136.1A patent/CN103739647B/zh active Active
- 2009-05-28 ES ES11191434.7T patent/ES2548402T3/es active Active
- 2009-05-28 DK DK09767367.7T patent/DK2278978T3/en active
- 2009-05-28 KR KR1020167002530A patent/KR101701404B1/ko active Active
- 2009-05-28 HU HUE09767367A patent/HUE027715T2/en unknown
-
2010
- 2010-11-18 ZA ZA2010/08256A patent/ZA201008256B/en unknown
-
2011
- 2011-12-15 US US13/327,628 patent/US8334279B2/en active Active
-
2012
- 2012-11-15 US US13/678,253 patent/US8673887B2/en active Active
-
2014
- 2014-01-27 US US14/164,779 patent/US9434758B2/en active Active
-
2015
- 2015-02-15 HK HK15101687.9A patent/HK1201184A1/en unknown
- 2015-06-09 JP JP2015116880A patent/JP6204408B2/ja active Active
-
2016
- 2016-08-05 US US15/229,947 patent/US9649320B2/en active Active
-
2017
- 2017-04-10 US US15/483,863 patent/US10206933B2/en active Active
- 2017-08-31 JP JP2017167132A patent/JP6356888B2/ja active Active
-
2018
- 2018-12-19 US US16/226,061 patent/US10857161B2/en active Active
-
2019
- 2019-08-12 HR HRP20191455 patent/HRP20191455T1/hr unknown
- 2019-09-04 CY CY20191100926T patent/CY1121984T1/el unknown
-
2020
- 2020-10-28 US US17/082,521 patent/US11833159B2/en active Active
-
2023
- 2023-10-27 US US18/496,122 patent/US20240285650A1/en active Pending
-
2024
- 2024-05-08 NL NL301273C patent/NL301273I2/nl unknown
- 2024-05-09 HU HUS2400013C patent/HUS2400013I1/hu unknown
- 2024-05-10 CY CY2024014C patent/CY2024014I2/el unknown
- 2024-05-15 FR FR24C1021C patent/FR24C1021I2/fr active Active
- 2024-06-04 FI FIC20240018C patent/FIC20240018I1/fi unknown
- 2024-06-13 LT LTPA2024518C patent/LTC2805720I2/lt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521964A5 (https=) | ||
| BRPI0909564A2 (pt) | composto para uso na fabicação de um medicamento para reduzir os sintomas de uma doença selecionada do grupo consistindo de distrofia muscular, artrite, traumatismo craniocerebral, lesão da medula espinal, sepsia, doença reumatica, arteroesclerose de câncer, diabetes tipo 1, diabetes tipo 2, doença renal de leptospirose, glaucoma, doença retinal, envelhecimento,dor de cabeça, dores, síndrome de dor regional complexa, hipertrofia cardíaca, deperdição muscular, desordens catabólicas, obesidade, retardo no crescimento fetal, hipercolesterolemia, doença cardíaca, insuficiência cardíaca crônica, isquemia/reperfusão, avc, aneurisma cerebral, angina pectoris, doença pulmonar, fibrose cística, lesão pulmonar induzida por ácido, hipertensãopulmonar, asma, doença pulmonar obstrutiva crônica, síndrome de sjogren, doença da membrana hialina, doença renal, doença glomerular, doença do fígado alcoólica, doenças do intestino, endometriose peritoneal, doenças da pele, sinusite nasal, mesotelioma, displasia ecodérmica anidrótica-id, doença de behcet, incontinencia pigmentar, tuberculose, asma, doença de crohn, colite, alergia ocular, apendicite, doença de paget, pancreatite, periodontite, endometriose, doença do intestino inflamatória, doença pulmonar inflamatória, doenças induzidas por sílica, apnéia de sono, aids, hiv-1, doenças autoimunes, síndrome antifosfolipídica, lúpus, lúpus nefrite, febre de malta familiar, síndrome de febre periódica hereditária, doenças de estresse psicossocial, doenças neuropatológicas, polineuropatia amiloidótica familiar, neuropatia inflamatória, doença de parkinson, esclerose múltipla, doença de alzheimer, esclerose lateral amiotrópica, doença de huntington, cataratas, e perda da audição e composição farmacêutica | |
| JP2013518881A5 (https=) | ||
| JP2012515724A5 (https=) | ||
| IL295237A (en) | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | |
| US12006328B2 (en) | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto | |
| CN101679287B (zh) | 烟碱型乙酰胆碱受体调节剂 | |
| JP2005194283A5 (https=) | ||
| ZA200505523B (en) | Asthma and allergic inflammation modulators | |
| NZ582056A (en) | Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation | |
| JP2014505095A5 (https=) | ||
| JP2018531289A5 (https=) | ||
| CN109153672B (zh) | Trpv4拮抗剂 | |
| JP2011500780A (ja) | 新規結晶形 | |
| WO2024108673A1 (en) | Triazine derivatives and methods of use thereof | |
| EP1727790A1 (en) | Phenylaminoethanol derivatives as beta2 receptor agonists | |
| ES2749657T3 (es) | Derivados de O-alquil-bencilidenguanidina y su uso terapéutico para el tratamiento de trastornos asociados a una acumulación de proteínas mal plegadas | |
| ES2214712T3 (es) | Hemisulfato nucleosido carbociclico y su uso en el tratamiento de infecciones viricas. | |
| HUP0202736A2 (hu) | Szubsztituált aromás gyűrűt tartalmazó vegyületek, eljárás előállításukra, ilyen vegyületeket tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
| NZ291862A (en) | 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1 -methanol succinate; preparative process and antiviral medicaments | |
| WO2014086098A1 (zh) | 环己烷胺类化合物及其作为抗精神分裂症药物的应用 | |
| US9676727B2 (en) | Myxovirus therapeutics, compounds, and uses related thereto | |
| CN102958926A (zh) | 作为抗组胺剂的卢帕他定盐 | |
| JP2021510168A5 (https=) | ||
| KR20100098563A (ko) | 아제티딘 유도체, 그의 제법 및 치료에서의 그의 적용 |